The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer—a report of two cases
- 1 June 2016
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 7 (3) , E45-E51
Abstract
Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker that is has been has been intensely studied and investigated as a surrogate marker in pancreatic cancer (PC). It is also commonly utilized in the clinical management of PC. We report two cases where normal range CA 19-9 level has been shown to be useful as a surrogate marker for following PC progression and response to treatment. Initially in our cases, both patients had a resectable tumor and their tumor markers were within normal range. In both cases the normal range CA 19-9 increase from the baseline was associated with corresponding progressive disease on imaging studies and CA 19-9 decline was in keeping with response to systemic and local therapy despite being within the normal range. To our knowledge, this is the first case report where we report the utility of serial normal values of CA 19-9 as a useful tool in following PC disease activity and in response to treatment. Clinicians should consider measuring serial normal values of CA 19-9 in patients with PC and normal range CA 19-9 which may help in assessing response to treatment in subset of this population.Keywords
This publication has 30 references indexed in Scilit:
- The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal2012
- CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.2006
- Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2004
- Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic populationJournal of Gastroenterology and Hepatology, 2004
- Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with GemcitabineJournal of Gastrointestinal Cancer, 2002
- A New Strategy for The Application of Ca19-9 in The Differentiation of Pancreaticobiliary Cancer: Analysis Using A Receiver Operating Characteristic CurveAmerican Journal of Gastroenterology, 1999
- CA19-9 as a Screening and Diagnostic Tool in Symptomatic PatientsPancreas, 1994
- Specific Antigen in Serum of Patients with Colon CarcinomaScience, 1981